File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: Efficacy and safety of single-agent sunitinib in treating patients with advanced hepatocelluar carcinoma after sorafenib failure: a prospective, open-label, phase II study

TitleEfficacy and safety of single-agent sunitinib in treating patients with advanced hepatocelluar carcinoma after sorafenib failure: a prospective, open-label, phase II study
Authors
KeywordsMedical sciences
Oncology medical sciences
Radiology and nuclear medicine pharmacy and pharmacology biology
Cytology and histology
Issue Date2011
PublisherAmerican Society of Clinical Oncology. The Journal's web site is located at http://www.jco.org/
Citation
The 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL., 4-8 June 2011. In Journal of Clinical Oncology, 2011, v. 29 n. 15 suppl., abstract no. 4082 How to Cite?
AbstractBACKGROUND: This is an open label and single arm phase II study to assess the efficacy and tolerability of sunitinib for the treatment of sorafenib-refractory advanced hepatocellular carcinoma (HCC) patients. METHODS: Between October, 2008 and October, 2010, eligible patients with advanced HCC and documented disease progression after sorafenib treatment received sunitinib 37.5 mg continuously at Queen Mary Hospital, Hong Kong. Response assessment was performed after every 8 weeks. The primary endpoint was time-to-progression (TTP) and the secondary endpoints were tumor response rate (RR), overall survival (OS) and safety. RESULTS: At the time of analysis, 38 patients were recruited in the trial. The median age was 56 years (range, 27-80) and all patients were in ECOG Performance Status 0-1. Ninety-five percent of patients were chronic hepatitis B carriers with underlying Child-Pugh A and B cirrhosis in 70% and 30% of the enrolled patients, respectively. Ten (25%) patients had tumor vascular invasion and 32 (80%) patients had extra-hepatic metastasis. Among 35 evaluable patients, RR was 6% with 2 patients achieved partial response and another 12 (34%) patients achieved stable disease. Overall, 40% of patients derived clinical benefits from sunitinib treatment for at least 8 weeks. The median TTP was 2.9 months (0.5-15) and OS was 5.2 months (1-22.5). Malaise (60%), neutropenia (45%) and diarrhea (36%) were the most commonly encountered adverse events, with nearly 30% of patients experienced grade 3 or 4 toxicity. No treatment-related death was reported. CONCLUSIONS: Sunitinib has substantial anti-tumour activity with manageable toxicity profile in treating sorafenib-refractory advanced HCC population. These data may imply sunitinib inhibits signaling pathways involved in sorafenib resistance and support the hypothesis of sequential use of antiangiogenic tyrosine kinase inhibitors in treating advanced HCC patients.
DescriptionGeneral Poster Session - Gastrointestinal (Noncolorectal) Cancer: abstract no. 4082
Persistent Identifierhttp://hdl.handle.net/10722/137890
ISSN
2015 Impact Factor: 20.982
2015 SCImago Journal Rankings: 9.204

 

DC FieldValueLanguage
dc.contributor.authorYau, Ten_US
dc.contributor.authorLeung, RCen_US
dc.contributor.authorWong, Hen_US
dc.contributor.authorChiu, Jen_US
dc.contributor.authorChan, Pen_US
dc.contributor.authorPang, Ren_US
dc.contributor.authorFan, STen_US
dc.contributor.authorPoon, RTPen_US
dc.date.accessioned2011-08-26T14:36:28Z-
dc.date.available2011-08-26T14:36:28Z-
dc.date.issued2011en_US
dc.identifier.citationThe 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL., 4-8 June 2011. In Journal of Clinical Oncology, 2011, v. 29 n. 15 suppl., abstract no. 4082en_US
dc.identifier.issn0732-183X-
dc.identifier.urihttp://hdl.handle.net/10722/137890-
dc.descriptionGeneral Poster Session - Gastrointestinal (Noncolorectal) Cancer: abstract no. 4082-
dc.description.abstractBACKGROUND: This is an open label and single arm phase II study to assess the efficacy and tolerability of sunitinib for the treatment of sorafenib-refractory advanced hepatocellular carcinoma (HCC) patients. METHODS: Between October, 2008 and October, 2010, eligible patients with advanced HCC and documented disease progression after sorafenib treatment received sunitinib 37.5 mg continuously at Queen Mary Hospital, Hong Kong. Response assessment was performed after every 8 weeks. The primary endpoint was time-to-progression (TTP) and the secondary endpoints were tumor response rate (RR), overall survival (OS) and safety. RESULTS: At the time of analysis, 38 patients were recruited in the trial. The median age was 56 years (range, 27-80) and all patients were in ECOG Performance Status 0-1. Ninety-five percent of patients were chronic hepatitis B carriers with underlying Child-Pugh A and B cirrhosis in 70% and 30% of the enrolled patients, respectively. Ten (25%) patients had tumor vascular invasion and 32 (80%) patients had extra-hepatic metastasis. Among 35 evaluable patients, RR was 6% with 2 patients achieved partial response and another 12 (34%) patients achieved stable disease. Overall, 40% of patients derived clinical benefits from sunitinib treatment for at least 8 weeks. The median TTP was 2.9 months (0.5-15) and OS was 5.2 months (1-22.5). Malaise (60%), neutropenia (45%) and diarrhea (36%) were the most commonly encountered adverse events, with nearly 30% of patients experienced grade 3 or 4 toxicity. No treatment-related death was reported. CONCLUSIONS: Sunitinib has substantial anti-tumour activity with manageable toxicity profile in treating sorafenib-refractory advanced HCC population. These data may imply sunitinib inhibits signaling pathways involved in sorafenib resistance and support the hypothesis of sequential use of antiangiogenic tyrosine kinase inhibitors in treating advanced HCC patients.-
dc.languageengen_US
dc.publisherAmerican Society of Clinical Oncology. The Journal's web site is located at http://www.jco.org/-
dc.relation.ispartofJournal of Clinical Oncologyen_US
dc.subjectMedical sciences-
dc.subjectOncology medical sciences-
dc.subjectRadiology and nuclear medicine pharmacy and pharmacology biology-
dc.subjectCytology and histology-
dc.titleEfficacy and safety of single-agent sunitinib in treating patients with advanced hepatocelluar carcinoma after sorafenib failure: a prospective, open-label, phase II studyen_US
dc.typeConference_Paperen_US
dc.identifier.emailYau, T: tyaucc@hku.hken_US
dc.identifier.emailPang, R: robertap@hku.hken_US
dc.identifier.emailFan, ST: stfan@hku.hken_US
dc.identifier.emailPoon, RTP: poontp@hku.hken_US
dc.identifier.authorityYau, T=rp01466en_US
dc.identifier.authorityPang, R=rp00274en_US
dc.identifier.authorityFan, ST=rp00355en_US
dc.identifier.authorityPoon, RTP=rp00446en_US
dc.identifier.hkuros189729en_US
dc.identifier.volume29en_US
dc.identifier.issue15 suppl.en_US
dc.description.otherThe 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL., 4-8 June 2011. In Journal of Clinical Oncology, 2011, v. 29 n. 15 suppl., abstract no. 4082-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats